{"id":2325,"date":"2015-02-01T12:07:00","date_gmt":"2015-02-01T11:07:00","guid":{"rendered":"https:\/\/der-arzneimittelbrief.com\/artikel\/2015\/die-700-e-tablette"},"modified":"2015-02-01T12:07:00","modified_gmt":"2015-02-01T11:07:00","slug":"die-700-e-tablette","status":"publish","type":"post","link":"https:\/\/der-arzneimittelbrief.com\/artikel\/2015\/die-700-e-tablette","title":{"rendered":"Die 700 \u20ac-Tablette"},"content":{"rendered":"<p>Der exorbitante Preis, den die Firma Gilead f\u00fcr das Hepatitis-C-Mittel Sofosbuvir (Sovaldi\u00ae) verlangt, erfordert eine grundlegende Diskussion dar\u00fcber, wie die Preise innovativer Arzneimittel festgelegt werden. Ein 12-w\u00f6chiger Therapiezyklus mit 84 Tabletten Sovaldi\u00ae kostet in Deutschland und in \u00d6sterreich derzeit um 60.000 \u20ac. Hieraus errechnet sich ein Preis pro Tablette von ca. 700 \u20ac. Die Produktionskosten [&hellip;]<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Der exorbitante Preis, den die Firma Gilead f\u00fcr das Hepatitis-C-Mittel Sofosbuvir (Sovaldi\u00ae) verlangt, erfordert eine grundlegende Diskussion dar\u00fcber, wie die Preise innovativer Arzneimittel festgelegt werden. Ein 12-w\u00f6chiger Therapiezyklus mit 84 Tabletten Sovaldi\u00ae kostet in Deutschland und in \u00d6sterreich derzeit um 60.000 \u20ac. Hieraus errechnet sich ein Preis pro Tablette von ca. 700 \u20ac. Die Produktionskosten [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[255,1281,1199,204,257,845,1671,843,846,3147],"class_list":["post-2325","post","type-post","status-publish","format-standard","hentry","category-allgemein","tag-arzneimittel","tag-arzneimittelmarkt","tag-arzneimittelpreise","tag-hepatitis-c","tag-medikamente","tag-patente","tag-patentschutz","tag-pharmaindustrie","tag-pharmazeutische-unternehmer","tag-sofosbuvir"],"_links":{"self":[{"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/posts\/2325","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/comments?post=2325"}],"version-history":[{"count":0,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/posts\/2325\/revisions"}],"wp:attachment":[{"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/media?parent=2325"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/categories?post=2325"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/tags?post=2325"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}